UK Markets close in 1 hr 7 mins
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • FTSE 250

    22,263.24
    -451.76 (-1.99%)
     
  • AIM

    1,132.08
    -24.37 (-2.11%)
     
  • GBP/EUR

    1.1942
    -0.0077 (-0.64%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • BTC-GBP

    24,879.95
    -1,484.03 (-5.63%)
     
  • CMC Crypto 200

    759.47
    -51.13 (-6.31%)
     
  • S&P 500

    4,287.42
    -110.52 (-2.51%)
     
  • DOW

    33,582.75
    -682.62 (-1.99%)
     
  • CRUDE OIL

    0 (0)
     
  • GOLD FUTURES

    1,836.10
    -6.50 (-0.35%)
     
  • NIKKEI 225

    27,522.26
    -250.64 (-0.90%)
     
  • HANG SENG

    24,965.55
    +13.25 (+0.05%)
     
  • DAX

    15,603.88
    -308.42 (-1.94%)
     
  • CAC 40

    7,068.59
    -125.57 (-1.75%)
     

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

·4-min read
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • ARWR
  • NVO
  • JNJ
  • DRNA
  • NVS
  • ALNY

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting